Currently there are 2.5 million pressure injuries (PIs) that occur every year. Consider the fact that in addition to the pain and suffering caused by PIs, the non-reimbursable costs to hospitals for treatment can be staggering, with a single PI event ranging from $20,000 to more than $150,000. Guidelines for care of patients at risk of PI specify skin assessments and body repositioning every 2 hours. Recently, adhesive foamy patches designed to minimize pressure, shear, and moisture of high-risk skin areas, have been marketed to hospitals with the claim of increasing prevention rates to 80%. However, treatment still relies on skin assessments.
Annually, over 60,000 deaths are directly linked to bedsores.
Currently, skin assessment relies on a visual inspection of the patient’s skin made by a nurse. This method has three key drawbacks; 1) inter/intra rater reliability is a function of staff training and knowledge, 2) inspections require one or more nurses to prioritize their time amid busy schedules, 3) inspections require manipulations of the patient, which can be uncomfortable or in some cases dangerous.
The costs for treatment can be staggering, with a single bed sore event ranging from $20,000 to (more than) $150,000.
Our solution eliminates the need for nurses to perform periodic visual assessments. We expect an increase in the prevention rate of hospital-acquired Stage 3 PI to 99.9%. Our solution consists of a disposable, adhesive patch (with the same benefits as a foamy patch) and bed-side unit that performs a three-dimensional tissue assessment in real-time. It monitors structural and functional tissue alterations induced by pressure, shear, microclimate, and temperature to detect the earliest signs of PIs.
Our solution 1) automatically performs PI staging using quantitative, repeatable and valid measures, 2) detects tissue alterations that originate on, or progress underneath the skin, before they become visible to the human eye, 3) monitors the severity of a PI continuously, alerting the nurses of a stage progression/regression, 4) optimizes patient re-positioning and minimizes unnecessary manipulations, and 5) removes regular skin assessments from nurses’ schedules.
DermaVision’s sensing patch eliminates the need for busy nurses to perform periodic visual assessments, and can detect 99% of hospital-acquired bedsores at Stage 1 or 2 when they can be treated inexpensively.